BS-194

Research use only, not for human use.

BS-194 is a potent, selective, orally bioactive CDK2 inhibitor with IC50 of 2.4 nM, displays 140-fold selectivity over CDK7 (IC50=378 nM); weakly inhibits CDK1, CDK5, CDK7, and CDK9 with IC50 of 30, 30, 250, and 90 nM.

BS-194 is a potent, selective, orally bioactive CDK2 inhibitor with IC50 of 2.4 nM, displays 140-fold selectivity over CDK7 (IC50=378 nM); weakly inhibits CDK1, CDK5, CDK7, and CDK9 with IC50 of 30, 30, 250, and 90 nM; shows inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases; inhibits human tumor xenografts and suppresses CDK substrate phosphorylation.

BS 194;BS194

Angiogenesis

CDK

CDK

——

——

1092443-55-4

385.47

C20H27N5O3

>98% (HPLC)

——

OC[C@@H](O)[C@@H](NC1=NC2=C(C(C)C)C=NN2C(NCC3=CC=CC=C3)=C1)CO

(2S,3S)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol

(-20℃)

With Ice Pack

≥ 2 years